Is MLTX or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media favor MLTX or XENE?

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 5 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.36 beat MoonLake Immunotherapeutics' score of 0.54 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ORKA or MLTX?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ORKA or MLTX more profitable?

Oruka Therapeutics' return on equity of -26.16% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media favor ORKA or MLTX?

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for Oruka Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat Oruka Therapeutics' score of 0.25 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ERAS or MLTX?

Erasca is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ERAS or MLTX more profitable?

Erasca's return on equity of -35.31% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media favor ERAS or MLTX?

In the previous week, Erasca had 18 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 25 mentions for Erasca and 7 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat Erasca's score of 0.04 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 0 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLTX or TVTX?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 6 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.31 beat MoonLake Immunotherapeutics' score of 0.54 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MoonLake Immunotherapeutics (MLTX) Competitors

$18.95 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$18.93 -0.02 (-0.08%)

As of 07/2/2026 07:40 PM Eastern

Compare

MLTX vs. XENE, ORKA, ERAS, AMRX, and TVTX

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MarketBeat compares MoonLake Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MoonLake Immunotherapeutics include Xenon Pharmaceuticals (XENE), Oruka Therapeutics (ORKA), Erasca (ERAS), Amneal Pharmaceuticals (AMRX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

How does MoonLake Immunotherapeutics compare to Xenon Pharmaceuticals?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

MoonLake Immunotherapeutics currently has a consensus target price of $24.21, indicating a potential upside of 27.78%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 26.64%. Given MoonLake Immunotherapeutics' higher probable upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals' return on equity of -49.23% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Xenon Pharmaceuticals	$7.50M	785.73	-$345.91M	-$4.70	N/A

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 5 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.36 beat MoonLake Immunotherapeutics' score of 0.54 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats MoonLake Immunotherapeutics on 8 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Oruka Therapeutics' return on equity of -26.16% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Oruka Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Oruka Therapeutics currently has a consensus price target of $134.30, indicating a potential upside of 57.61%. MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 27.78%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Oruka Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for Oruka Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat Oruka Therapeutics' score of 0.25 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oruka Therapeutics beats MoonLake Immunotherapeutics on 7 of the 12 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Erasca's return on equity of -35.31% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Erasca has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Erasca is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

In the previous week, Erasca had 18 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 25 mentions for Erasca and 7 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat Erasca's score of 0.04 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	0 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Erasca presently has a consensus target price of $20.11, indicating a potential upside of 8.89%. MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.78%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Summary

Erasca beats MoonLake Immunotherapeutics on 7 of the 13 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Amneal Pharmaceuticals has a net margin of 4.01% compared to MoonLake Immunotherapeutics' net margin of 0.00%. MoonLake Immunotherapeutics' return on equity of -85.15% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Amneal Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.05B	1.80	$72.06M	$0.38	45.13
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for Amneal Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat Amneal Pharmaceuticals' score of 0.12 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals currently has a consensus price target of $15.80, indicating a potential downside of 7.87%. MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 27.78%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Amneal Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Travere Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Travere Therapeutics	$490.73M	10.78	-$25.55M	-$0.23	N/A

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 6 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.31 beat MoonLake Immunotherapeutics' score of 0.54 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

MoonLake Immunotherapeutics currently has a consensus target price of $24.21, indicating a potential upside of 27.78%. Travere Therapeutics has a consensus target price of $52.08, indicating a potential downside of 8.47%. Given MoonLake Immunotherapeutics' higher possible upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Summary

Travere Therapeutics beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.40B	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-4.90	21.61	28.02	24.70
Price / Sales	N/A	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	4.44	8.66	10.96	6.46
Net Income	-$227.32M	$23.81M	$3.57B	$337.01M
7 Day Performance	-4.77%	3.39%	2.12%	1.69%
1 Month Performance	5.87%	10.81%	5.25%	3.81%
1 Year Performance	-59.13%	62.61%	33.29%	23.90%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	3.2427 of 5 stars	$18.95 flat	$24.21 +27.8%	-59.1%	$1.40B	N/A	N/A	2	Analyst Forecast Insider Trade
XENE Xenon Pharmaceuticals	3.9997 of 5 stars	$60.11 0.0%	$77.20 +28.4%	+75.7%	$5.80B	$7.50M	N/A	210	News Coverage Positive News
ORKA Oruka Therapeutics	3.1357 of 5 stars	$94.69 +2.4%	$131.30 +38.7%	+576.5%	$5.72B	N/A	N/A	N/A	Analyst Downgrade Gap Up
ERAS Erasca	1.5444 of 5 stars	$18.04 -1.4%	$20.11 +11.5%	+1,238.4%	$5.60B	N/A	N/A	120	Trending News Gap Down
AMRX Amneal Pharmaceuticals	2.0412 of 5 stars	$17.40 +0.6%	$15.80 -9.2%	+100.4%	$5.54B	$3.02B	45.74	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. XENE, ORKA, ERAS, AMRX, and TVTX

How does MoonLake Immunotherapeutics compare to Xenon Pharmaceuticals?

Summary

How does MoonLake Immunotherapeutics compare to Oruka Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Erasca?

Summary

How does MoonLake Immunotherapeutics compare to Amneal Pharmaceuticals?

Summary

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. XENE, ORKA, ERAS, AMRX, and TVTX

How does MoonLake Immunotherapeutics compare to Xenon Pharmaceuticals?

Do analysts recommend MLTX or XENE?

Is MLTX or XENE more profitable?

Do insiders and institutionals have more ownership in MLTX or XENE?

Which has better earnings & valuation, MLTX or XENE?

Does the media favor MLTX or XENE?

Which has more volatility and risk, MLTX or XENE?

Summary

How does MoonLake Immunotherapeutics compare to Oruka Therapeutics?

Which has more volatility & risk, ORKA or MLTX?

Is ORKA or MLTX more profitable?

Which has preferable valuation & earnings, ORKA or MLTX?

Do analysts recommend ORKA or MLTX?

Do insiders & institutionals have more ownership in ORKA or MLTX?

Does the media favor ORKA or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Erasca?

Is ERAS or MLTX more profitable?

Which has more risk and volatility, ERAS or MLTX?

Which has stronger earnings and valuation, ERAS or MLTX?

Does the media favor ERAS or MLTX?

Do institutionals and insiders have more ownership in ERAS or MLTX?

Do analysts recommend ERAS or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Amneal Pharmaceuticals?

Is AMRX or MLTX more profitable?

Which has better valuation and earnings, AMRX or MLTX?

Do institutionals & insiders have more ownership in AMRX or MLTX?

Does the media favor AMRX or MLTX?

Do analysts prefer AMRX or MLTX?

Which has more risk & volatility, AMRX or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

Which has preferable valuation and earnings, MLTX or TVTX?

Does the media refer more to MLTX or TVTX?

Do insiders & institutionals have more ownership in MLTX or TVTX?

Is MLTX or TVTX more profitable?

Do analysts rate MLTX or TVTX?

Which has more volatility and risk, MLTX or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools